Our results revealed that RRM2 was a hazardous prognostic factor for glioma, and the subgroup with a higher expression level of RRM2 harbored more immune infiltration and expressed more immunotherapy-related markers, agreeing with the conclusions of previous studies. This evidence concerns the gene RRM2 and central nervous system cancer.